CSTL Castle Biosciences

Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2

FRIENDSWOOD, Texas--(BUSINESS WIRE)--

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2022, after the close of market on Wednesday, Nov. 2, 2022.

Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.

Conference Call and Webcast Details

A live webcast of the conference call can be accessed here: or via the webcast link on the Investor Relations page of the Company’s , . Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.

To access the live conference call via phone, please dial 1 844 200 6205 from the United States, or internationally, at least 10 minutes prior to the start of the call, using the access code 723381.

There will be a brief Question & Answer session following management commentary.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit and connect with us on , , and .

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

EN
19/10/2022

Underlying

CSTLCastle Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE
Free
CSTL Castle Bioscien...

Prospective, Multi-center Study Published in Future Oncology Demonstra...

Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) by DecisionDx-Melanoma’s i31-SLNB Only 1.4% SLN positivity was observed in patients with T1b–T2a tumors predicted to have less than 5% risk The Company will ho...

March 13, 2026 1 EN
 PRESS RELEASE
Free
CSTL Castle Bioscien...

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective M...

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (SLNB) if the predicted SLN positivity rate is less than 5%. This report shows that patients with a less than 5% predicted risk of SLN positivity by the DecisionDx-Melanoma test had an actual SLN positivity rate of just 2.6%...

March 9, 2026 1 EN
 PRESS RELEASE
Free
CSTL Castle Bioscien...

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma...

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix. “The initial reports ...

March 4, 2026 1 EN
 PRESS RELEASE
Free
CSTL Castle Bioscien...

Castle Biosciences Announces Grand Opening of New Corporate Headquarte...

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and oth...

March 3, 2026 1 EN
 PRESS RELEASE
Free
CSTL Castle Bioscien...

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed out an outstanding year...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch